Objective To investigate the effect of aspirin and cilostazol on interleukin-6 (IL-6) and high sensitive C reactive protein (hsCRP) and platelet-activating factor acetylhydrolase (PAF-AH) in acute coronary syndrome (ACS) patients and the difference between them.
Methods 72 patients with ACS were randomly divided into two groups: the aspirin group (n=34) and cilostazol group (n=38). All patients were given routine therapy including rest, oxygen inhaling, anticoagulating, reducing blood lipid levels, controlling the blood pressure. The patients in the aspirin group were given aspirin 0.1 g every day in addition. The patients in the cilostazol group were given cilostazol 0.1 g twice a day underlying the routine therapy. The course of treatment was 4 weeks. Observe the IL-6 and hsCRP and PAF-AH in serum and on peripheral blood mononuclear cells of the patients before and after treatment.
Result The basic characteristics of the two groups were identical (p>0.05). The content of IL-6 and hsCRP were all significantly decreased after therapy (p<0.05), and the content of PAF-AH were significantly increased after therapy (p<0.05). The content of IL-6 (25.9±7.5 vs 20.3±9.8 pg/ml) and hsCRP (9.5±2.1 vs 6.1±1.9 g/l) in aspirin group (after treatment) were significantly higher than those in cilostazol group (after treatment)(p<0.05), and PAF-AH (27.2±5.6 vs 36.8±2.6 μmolċmin−1l−1) in aspirin group (after treatment) were significantly lower than those in cilostazol group (after treatment) (p<0.05).
Conclution Aspirin and cilostazol can decrease IL-6 and hsCRP level and increase PAF-AH level in ACS patients. And cilostazol is more effective than aspirin to inhibit the inflammatory response in ACS patients.
- acute coronary syndrome
- high sensitive C reactive protein
- platelet-activating factor acetylhydrolase
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.